Analysts Set Masimo Co. (NASDAQ:MASI) Price Target at $179.67

Masimo Co. (NASDAQ:MASIGet Free Report) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $179.67.

Several equities research analysts have recently weighed in on MASI shares. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. BTIG Research boosted their price objective on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Raymond James raised their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Wells Fargo & Company increased their price target on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, Piper Sandler lifted their price objective on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th.

Get Our Latest Stock Report on MASI

Masimo Trading Up 2.7 %

Shares of Masimo stock opened at $175.18 on Friday. The business has a fifty day simple moving average of $170.75 and a 200-day simple moving average of $143.51. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $180.97. The firm has a market cap of $9.38 billion, a price-to-earnings ratio of 120.81 and a beta of 1.01. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASIGet Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.63 EPS. On average, equities analysts forecast that Masimo will post 4.1 EPS for the current fiscal year.

Institutional Trading of Masimo

Several large investors have recently modified their holdings of MASI. UMB Bank n.a. lifted its position in Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 123 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares during the period. Trust Co. of Vermont acquired a new position in shares of Masimo during the 4th quarter worth about $33,000. NBC Securities Inc. boosted its stake in Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 73 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 200 shares during the last quarter. 85.96% of the stock is owned by institutional investors.

About Masimo

(Get Free Report

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Further Reading

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.